Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 4, 2010, Pages

  Liu, Yuying ^a   Bledsoe, Grant ^b   Hagiwara, Makato ^a   Yang, Zhi Rong ^a   Shen, Bo ^a   Chao, Lee ^a   Chao, Julie ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CHARLESTON SOUTHERN UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Fibrosis; Inflammation

Indexed keywords

ANGIOTENSIN II; COLLAGEN; GELATINASE A; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; LIPID PEROXIDASE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUPEROXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE KALLIKREIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT;

EID: 77950830599     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00518.2009     Document Type: Article

References (36)

1. Azizi M, Emanueli C, Peyrard S, Maddedu P, Alhenc-Gelas F, Campbell DJ. Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins exretion in man. J Hypertens 26: 714-720, 2008.
2. Basile DP, Fredrich K, Alausa M, Vio CP, Liang M, Rieder MR, Greene AS, Cowley AW Jr. Identification of persistently altered gene expression in the kidney after functional recovery from ischemic acute renal failure. Am J Physiol Renal Physiol 288: F953-F963, 2005.
3. Bledsoe G, Crickman S, Mao J, Xia CF, Murakami H, Chao L, Chao J. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant 21: 624-633, 2006.
4. Bledsoe G, Shen B, Yao Y, Zhang JJ, Chao L, Chao J. Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery. Hum Gene Ther 17: 545-555, 2006.
5. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292: F905-F911, 2007.
6. Chao J, Margolius HS. Isozymes of rat urinary kallikrein. Biochem Pharmacol 28: 2071-2079, 1979.
7. Chao J, Yin H, Gao L, Hagiwara M, Shen B, Yang ZR, Chao L. Tissue kallikrein elicits cardioprotection by direct kinin B2 receptor activation independent of kinin formation. Hypertension 52: 715-720, 2008.
8. Chiang WC, Lin SL, Chen YM, Wu KD, Tsai TJ. Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment. Nephrology 13: 198-203, 2008.
9. Churchill PC, Churchill MC, Bidani AK, Rabito SF. Kallikrein excretion in Dahl salt-sensitive and salt-resistant rats with native and transplanted kidneys. Am J Physiol Renal Fluid Electrolyte Physiol 269: F710-F717, 1995.
10. De Cavanagh EM, Fraga CG, Ferder L, Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am J Physiol Regul Integr Comp Physiol 272: R514-R518, 1997.
11. 2-terminal kinase activation and proliferation of human mesangial cells via redox-sensitive transactivation of the EGFR. Am J Physiol Renal Physiol 293: F1889-F1897, 2007.
12. Fujisawa Y, Nagai Y, Miyatake A, Takei Y, Miura K, Shoukouji T, Nishiyama A, Kimura S, Abe Y. Renal effects of a new member of adrenomedullin family, adrenomedullin2, in rats. Eur J Pharmacol 497: 75-80, 2004.
13. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
14. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
15. Hagiwara M, Shen B, Chao L, Chao J. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther 19: 807-819, 2008.
16. Hecquet C, Tan F, Marcic BM, Erdos EG. Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 58: 828-836, 2000.
17. Jin L, Beswick RA, Yamamoto T, Palmer T, Taylor TA, Pollock JS, Pollock DM, Brands MW, Webb RC. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats. J Physiol Pharmacol 57: 343-357, 2006.
18. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003.
19. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24: 195-204, 1994.
20. Kimura K, Onodera K, Oike Y, Yamabe H, Numahata H, Kikuchi K, Hanada S. A clinical study on urinary kallikrein in patients with renal diseases. Adv Exp Med Biol 120B: 549-559, 1979.
21. Kumar KV, Shifow AA, Naidu MUR, Ratnakar KS. Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats. Life Sci 66: 2603-2611, 2000.
22. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201-1209, 2003.
23. Liu Y, Rajur K, Tolbert E, Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58: 2028-2043, 2000.
24. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 214: 11-16, 1993.
25. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharm Sci 99: 6-38, 2005.
26. Paul SM, Christopher SW, Shakil A. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 24: 354-365, 2004.
27. Pizard A, Richer C, Bouby N, Picard N, Meneton P, Azizi M, Alhenc-Gelas F. Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney. Biol Chem 389: 701-706, 2008.
28. Rajiv A, Ruth CC, David GW. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin Nephrol 24: 101-114, 2004.
29. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358: 771-783, 2008.
30. Shimamoto K, Chao J, Margolius HS. The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements. J Clin Endocrinol Metab 51: 840-848, 1980.
31. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 132: 345-352, 1983.
32. Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95: 1710-1716, 1995.
33. Wang C, Chen YP, Chao L, Chao J. Regulatory elements in the promoter region of the renal kallikrein gene in normotensive vs hypertensive rats. Biochem Biophys Res Commun 217: 113-122, 1995.
34. Xia CF, Bledsoe G, Chao L, Chao J. Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats. Am J Physiol Renal Physiol 289: F622-F631, 2005.
35. Zhang JJ, Bledsoe G, Kato K, Chao L, Chao J. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66: 722-732, 2004.
36. Zheng JS, Yang XQ, Lookingland KJ, Fink GD, Hesslinger C, Kapatos G, Kovesdi I, Chen AF. Gene transfer of human guanosine 5′-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation 108: 1238-1245, 2003.